Navigation Links
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced completion of the company's Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response.

AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production.

Results from the Phase 1 trial show that AM103 is safe and well-tolerated at doses up to 1,000 mg per day with no evidence of significant side effects. The systemic exposure of AM103 increased linearly from 50 mg to 1,000 mg.

Pharmacodynamic data demonstrated a robust and statistically significant reduction of LTB4 and LTE4 in a dose-dependent manner. "The results from this trial meet and even exceed our expectations for safety, and provide pharmacodynamic evidence consistent with this mechanism of action," said Peppi Prasit, Amira's chief scientific officer. "The half-life of up to 10 hours also gives us the opportunity to evaluate once-daily dosing in a Phase 2 trial, which we expect to start in 2008."

"Based on this very favorable profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2 study with AM103 in asthmatic patients," said Bob Baltera, Amira's chief executive
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... In an article based ... guest author addressed the topic of treating back pain caused by a disrupted disk ... shown to slightly improve physical function in patients suffering from a herniated disk, the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:8/31/2015)... ... , ... The Bay Pines VA Healthcare System (VAHCS) remains focused ... more doctors and nurses and expanding existing facilities and services. Spine surgery will ... Anthony Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... the Joint Replacement Surgery Program at Monmouth, was one of the first doctors ... decade, the results of this new approach have been impressive: faster recovery, decreased ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
Breaking Medicine News(10 mins):Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... opened the channels to make available a line of 150 ... move has elevated the position of the shopping conglomerate as ... ,Last year, Walmex's parent company, Wal-Mart Stores Inc. led ... for $4 per prescription. ,According to the statement ...
... enthralled as spiritual counselor Sadguru Jaggi Vasudev stressed on// the ... being a moral science lesson full of spiritual jargon, the ... a simple talk backed up with tips on mental control. ... look like a mess. Similarly our mind, which has a ...
... thing and to realize that it could send your cash reserves// ... just be the last nail in the coffin. ,Cancer ... Ontario hospitals to find reprieve with newer and more effective ... but are frequently prescribed by Oncologists. ,Julia Lelik, a ...
... authenticated about the beneficial aspects of tea, scientists have ... ,Scientists have earlier shown that antioxidant properties ... disease. They had also said that drinking tea could ... system attacks itself by mistake. ,Some earlier ...
... Canadian Cancer Society discloses that nearly 65% of children from ... ultra violet rays using artificial tanning equipments. ,The ... recommendation that children under the age of 18 be prevented ... ,Skin cancer is one of the most common forms ...
... a blow for the pro-choice sections, New York Eliot Spitzer ... strengthen abortion rights. ,Only last week a conservative-dominated ... signed by President Bush in 2003. The ban criminalizes abortions ... often the safest and best to protect women's health. ...
Cached Medicine News:Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Cancer – Flushes Flesh and Fund 2Health News:Dangerous Side Effects of Tea Exposed 2Health News:Artificial Tanning Causes Concern 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2
(Date:8/31/2015)...  Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a ... of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, ... four investor conferences in September. , ... Company, LLC Emerging Growth Conference in ... , President & Chief Executive Officer, will present a ...
(Date:8/31/2015)... Israel , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the ... commercializes biomedical innovations in ophthalmology and cancer diagnostics, ... Technologies (TASE: MCTC), has identified several new genetic ... the jawbone in patients treated with bisphosphonate drugs ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: